Birdwatch Note
2024-12-01 13:08:08 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
ワクチンの有効性は変異株や、時間経過とともに低下しました(例えば厚労省の下記の研究紹介を参照)。 https://www.mhlw.go.jp/content/10900000/31_effective.pdf しかし、例えば２１年前半に流行したアルファ株への有効性は、販売後データのメタアナリシスが報告されており、臨床試験に匹敵する有効性が、世界中で確認されています。 https://link.springer.com/article/10.1186/s12916-022-02397-y/figures/1 mRNAワクチンはアルファ変異への有効性が90.1%と本文にあります。 https://link.springer.com/article/10.1186/s12916-022-02397-y#Fig1 日本でもアルファ変異の時の２回接種後２週間以降の有効性は95%だった事が下記の表3-(b)で紹介されています(なお１回接種後２週間以内も有効性はマイナスではありません)。 https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10614-covid19-55.html
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1863186492325286148
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1863208459598193111
- noteId - 1863208459598193111
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1733058488164
- tweetId - 1863186492325286148
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 1
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- ワクチンの有効性は変異株や、時間経過とともに低下しました(例えば厚労省の下記の研究紹介を参照)。 https://www.mhlw.go.jp/content/10900000/31_effective.pdf しかし、例えば２１年前半に流行したアルファ株への有効性は、販売後データのメタアナリシスが報告されており、臨床試験に匹敵する有効性が、世界中で確認されています。 https://link.springer.com/article/10.1186/s12916-022-02397-y/figures/1 mRNAワクチンはアルファ変異への有効性が90.1%と本文にあります。 https://link.springer.com/article/10.1186/s12916-022-02397-y#Fig1 日本でもアルファ変異の時の２回接種後２週間以降の有効性は95%だった事が下記の表3-(b)で紹介されています(なお１回接種後２週間以内も有効性はマイナスではありません)。 https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/10614-covid19-55.html
Note Ratings
| rated at | rated by | |
| 2024-12-02 08:16:01 -0600 | Rating Details | |
| 2024-12-02 07:50:25 -0600 | Rating Details | |
| 2024-12-02 05:56:59 -0600 | Rating Details | |
| 2024-12-02 04:37:41 -0600 | Rating Details | |
| 2024-12-02 04:22:52 -0600 | Rating Details | |
| 2024-12-02 03:55:58 -0600 | Rating Details | |
| 2024-12-01 23:10:01 -0600 | Rating Details | |
| 2024-12-01 21:55:16 -0600 | Rating Details | |
| 2024-12-01 20:55:13 -0600 | Rating Details | |
| 2024-12-01 20:35:19 -0600 | Rating Details | |
| 2024-12-01 19:21:55 -0600 | Rating Details | |
| 2024-12-01 18:37:26 -0600 | Rating Details | |
| 2024-12-01 17:58:50 -0600 | Rating Details | |
| 2024-12-01 17:53:51 -0600 | Rating Details | |
| 2024-12-01 16:54:11 -0600 | Rating Details | |
| 2024-12-01 16:46:01 -0600 | Rating Details | |
| 2024-12-01 16:34:09 -0600 | Rating Details | |
| 2024-12-01 16:34:08 -0600 | Rating Details | |
| 2024-12-01 16:30:33 -0600 | Rating Details | |
| 2024-12-01 16:29:44 -0600 | Rating Details | |
| 2024-12-01 15:51:43 -0600 | Rating Details | |
| 2024-12-01 15:50:20 -0600 | Rating Details | |
| 2024-12-01 15:32:18 -0600 | Rating Details | |
| 2024-12-01 15:22:26 -0600 | Rating Details | |
| 2024-12-01 14:36:39 -0600 | Rating Details | |
| 2024-12-01 14:36:23 -0600 | Rating Details | |
| 2024-12-01 13:00:48 -0600 | Rating Details | |
| 2024-12-01 12:19:56 -0600 | Rating Details | |
| 2024-12-01 11:34:02 -0600 | Rating Details | |
| 2024-12-01 11:05:55 -0600 | Rating Details | |
| 2024-12-01 09:23:56 -0600 | Rating Details | |
| 2024-12-01 09:22:53 -0600 | Rating Details | |
| 2024-12-01 09:01:15 -0600 | Rating Details | |
| 2024-12-01 08:59:27 -0600 | Rating Details | |
| 2024-12-01 08:27:41 -0600 | Rating Details | |
| 2024-12-01 08:07:47 -0600 | Rating Details | |
| 2024-12-01 08:02:47 -0600 | Rating Details | |
| 2024-12-01 08:02:25 -0600 | Rating Details | |
| 2024-12-01 07:59:41 -0600 | Rating Details | |
| 2024-12-01 07:53:05 -0600 | Rating Details | |
| 2024-12-01 07:51:52 -0600 | Rating Details | |
| 2024-12-01 07:50:47 -0600 | Rating Details | |
| 2024-12-01 07:41:22 -0600 | Rating Details | |
| 2024-12-01 07:40:50 -0600 | Rating Details | |
| 2024-12-01 07:37:17 -0600 | Rating Details | |
| 2024-12-01 07:31:56 -0600 | Rating Details | |
| 2024-12-01 07:30:10 -0600 | Rating Details | |
| 2024-12-01 07:30:05 -0600 | Rating Details | |
| 2024-12-01 07:28:10 -0600 | Rating Details | |
| 2024-12-01 07:26:02 -0600 | Rating Details | |
| 2024-12-01 07:23:32 -0600 | Rating Details | |
| 2024-12-01 07:18:18 -0600 | Rating Details | |
| 2024-12-01 07:17:09 -0600 | Rating Details | |
| 2024-12-01 07:17:05 -0600 | Rating Details | |
| 2024-12-01 07:16:02 -0600 | Rating Details | |
| 2024-12-01 07:11:45 -0600 | Rating Details | |
| 2024-12-03 00:05:33 -0600 | Rating Details | |
| 2024-12-02 08:16:46 -0600 | Rating Details | |
| 2024-12-01 17:07:41 -0600 | Rating Details | |
| 2024-12-01 13:49:25 -0600 | Rating Details | |
| 2024-12-01 11:38:18 -0600 | Rating Details | |
| 2024-12-01 09:50:50 -0600 | Rating Details | |
| 2024-12-01 07:46:10 -0600 | Rating Details | |
| 2024-12-01 07:43:50 -0600 | Rating Details | |
| 2024-12-01 07:32:25 -0600 | Rating Details | |
| 2024-12-01 07:27:53 -0600 | Rating Details | |
| 2024-12-01 07:18:59 -0600 | Rating Details | |
| 2024-12-01 07:16:21 -0600 | Rating Details | |
| 2024-12-01 07:11:22 -0600 | Rating Details | |
| 2024-12-01 07:08:57 -0600 | Rating Details |